# Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

> **NCT03425539** · PHASE3 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Lucerastat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03425539
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2021-08-17
- **Final completion:** 2021-09-02
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425539, "Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03425539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*